WAVE Life Sciences (FRA:1U5) ROCE %: -23.40% (As of Mar. 2026)


FRA:1U5 WAVE Life Sciences Ltd FRA:1U5
59 GF Score
Price €4.72
GF Value €3.58
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is WAVE Life Sciences ROCE %?

WAVE Life Sciences FRA:1U5 -5.22% 59 ROCE % is -23.40% as of Mar. 2026. GuruFocus rates FRA:1U5 with a GF Score™ of 59/100 and a GF Value™ of €3.58 (Modestly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. WAVE Life Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -23.40%.

WAVE Life Sciences  (FRA:1U5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

WAVE Life Sciences ROCE % Related Terms

WAVE Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for WAVE Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WAVE Life Sciences ROCE % Chart

WAVE Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.68 -155.90 -82.13 -67.68 -52.97

WAVE Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.53 -111.26 -139.43 -64.67 -23.40
FRA:1U5
59GF Score
WAVE Life Sciences Ltd FRA:1U5
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WAVE Life Sciences ROCE % Calculation

WAVE Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-183.937/( ( (336.358 - 105.96) + (545.278 - 81.186) )/ 2 )
=-183.937/( (230.398+464.092)/ 2 )
=-183.937/347.245
=-52.97 %

WAVE Life Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-108.292/( ( (545.278 - 81.186) + (504.766 - 43.104) )/ 2 )
=-108.292/( ( 464.092 + 461.662 )/ 2 )
=-108.292/462.877
=-23.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -23.40% mean?
WAVE Life Sciences (FRA:1U5) has a ROCE % of -23.40% as of Mar. 2026.
Is WAVE Life Sciences' ROCE % too high?
WAVE Life Sciences' current ROCE % is -23.40%. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' ROCE % compare to AVLN and COAG?
WAVE Life Sciences' ROCE % of -23.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. WAVE Life Sciences's current ROCE % is -23.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.58, compared to a current price of €4.72 — trading 31.8% above its estimated fair value. The current ROCE % is -23.40%. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current ROCE % is -23.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?

Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued. The current stock price of €4.72 is trading 31.8% above its estimated GF Value™ of €3.58. GuruFocus considers WAVE Life Sciences to be Modestly Overvalued.

Key valuation signals for FRA:1U5:

  • ROCE %: -23.40%
  • GF Value™: €3.58 vs. price of €4.72 (31.8% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WAVE Life Sciences Business Description

Other Exchanges WVE:USA1U5:Germany
Address 7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score

Get the complete analysis for FRA:1U5

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.72
Price
€3.58
GF Value